CeriBell (NASDAQ:CBLL) CFO Scott Blumberg Sells 1,387 Shares

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 1,387 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $18.00, for a total transaction of $24,966.00. Following the sale, the chief financial officer owned 147,683 shares in the company, valued at $2,658,294. This represents a 0.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Trading Up 0.2%

NASDAQ CBLL traded up $0.03 during trading on Tuesday, hitting $18.80. The stock had a trading volume of 187,155 shares, compared to its average volume of 322,889. CeriBell, Inc. has a one year low of $10.85 and a one year high of $24.33. The stock has a 50 day simple moving average of $19.08 and a 200 day simple moving average of $19.19. The stock has a market capitalization of $713.27 million, a price-to-earnings ratio of -11.53 and a beta of 0.99. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The company had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. Sell-side analysts predict that CeriBell, Inc. will post -1.69 earnings per share for the current year.

Analyst Ratings Changes

CBLL has been the subject of a number of research reports. Weiss Ratings downgraded shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 12th. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. Finally, Canaccord Genuity Group cut their target price on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and a consensus target price of $22.20.

Institutional Investors Weigh In On CeriBell

A number of institutional investors and hedge funds have recently made changes to their positions in CBLL. CenterBook Partners LP boosted its position in shares of CeriBell by 448.0% during the third quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock worth $5,476,000 after buying an additional 389,584 shares during the period. JPMorgan Chase & Co. lifted its stake in CeriBell by 8.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 411,180 shares of the company’s stock worth $4,724,000 after acquiring an additional 31,177 shares in the last quarter. GSA Capital Partners LLP purchased a new position in CeriBell during the 3rd quarter valued at about $158,000. TimesSquare Capital Management LLC boosted its holdings in CeriBell by 2.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 817,645 shares of the company’s stock valued at $9,395,000 after acquiring an additional 20,700 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new stake in CeriBell during the first quarter worth about $341,000.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.